Covaxin shows 50 per cent effectiveness against symptomatic Covid in real-world assessment: Lancet study

New Delhi: Two doses of Covaxin are 50 per cent effective against symptomatic Covid, according to the first real-world assessment of India’s indigenous coronavirus vaccine published in The Lancet Infectious Diseases journal.

“Our study offers a more complete picture of how BBV152 performs in the field and should be considered in the context of Covid-19 surge conditions in India, combined with the possible immune evasive potential of the delta variant,” Manish Soneja, an additional professor of medicine at AIIMS in New Delhi, said in a statement referring to the vaccine’s scientific name.

The latest study assessed 2,714 hospital workers at the All India Institute of Medical Sciences (AIIMS) in Delhi, from April 15–May 15, who were symptomatic and underwent RT-PCR test for Covid detection.